Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N. Engl. J. Med.

Title: The New England journal of medicine

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Oct 29 2015

Volume: 373

Issue: 18

Affiliations

[1 ] From the Institute of Hematology, Department of Medicine, and Centro di Ricerca Emato-Oncologico (CREO), University of Perugia, and Ospedale Santa Maria della Misericordia, Perugia (E.T., L.D.C., F.F., S.A., M.C., M.P.M., B.F.), the Department of Experimental, Diagnostic, and Specialty Medicine, Units of Hematology and Hematopathology, Bologna University School of Medicine, Bologna (A.B., S.A.P., P.L.Z.), Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, Dipartimento di Science Mediche Sperimentali e Cliniche, Azienda Ospedaliero Universitaria, Udine (F.Z.), the Department of Cellular Biotechnologies and Hematology, Division of Hematology, Sapienza University, Rome (A.P., R.F.), the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Regionale San Carlo, Potenza (M.C.), the Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (D.R.), Hematology Unit, Ospedale Ferrarotto, Catania (G.M.), the Department of Onco-Hematology, Fondazione IRCCS, Policlinico San Matteo, Pavia (M.V.), Hematology Unit, Spedali Civili, Brescia (A. Anastasia), the Department of Medicine, Section of Hematology, University of Verona, Verona (A. Ambrosetti), Onco-Hematology Unit, Fondazione di Ricerca e Cura S.S. Giovanni Paolo II, Campobasso (V.F.), Institute of Hematology 1, IRCCS, Azienda Ospedaliero Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa (A.M.C.), the Department of Hematology, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona (P.L.), and the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (A.R.) - all in Italy; Leukemia Service (J.H.P., S.S.C., R.L.L., O.A-W., M.S.T.,) and Dermatology Service (M.E.L.), the Department of Medicine, Human Oncology and Pathogenesis Program (S.S., Y.R.C., E.K., R.L.L., C.Y.P., M.F.B., O.A-W.), the Departments of Epidemiology and Biostatistics (S.D.), Pathology (C.Y.P.), and Pharmaco

Article

Mid ID: EMS67691

DOI: 10.1056/NEJMoa1506583

PubMed ID: 26352686

SO-VID: 56b3d4ea-a2bb-4a93-9e9b-5d48af02cf45

History

Data availability:

Comments

Comment on this article

scite_

Cited by 112

See all cited by

- Version 1